We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/4/2023 17:43 | hTTps://www.bbc.co.u | aidenabettin | |
19/4/2023 15:53 | Lost my nerve! Bought back at 119.6. Not a lot on the turn, but it all nibbles away at the holding cost. No doubt it will turn out that I should have waited for a better re-entry price, but this is a share I like, so there is something to be said for not being greedy, and with a profit on the table on a 24 hr out and back, I took it. | 1knocker | |
19/4/2023 00:15 | Yes, thanks SMCNI. | philanderer | |
18/4/2023 17:40 | Thanks for the info SMCNI1968 | our haven | |
18/4/2023 17:20 | A Johnson a Johnson drug that was expected to compete with Astra's Tagrisso flopped in its trials. | smcni1968 | |
18/4/2023 14:46 | My sell order has triggered at at 123.4 Now all that remains is to get back in cheaper before the next ex div date. Plenty of time, just need to hold my patience. Its a volatile market. My last round trip here was a sale at 118.5, repurchase at 110 and a bit. Still mulling the limit order for the next repurchase. Another 110 would be great, but maybe pushing my luck. 116, even 118, would be fine. | 1knocker | |
18/4/2023 14:29 | Falling bsck a little now. Can't see any news. | philanderer | |
18/4/2023 14:07 | I am obviously missing something. Buying has just gone mad. | our haven | |
17/4/2023 14:29 | A reasonably neat summary in today’s Times How to follow the smartest money to the best stocks | srichardson8 | |
13/4/2023 22:52 | The same people who insisted we had the vaccine to keep our jobs. | angus mcoatup | |
13/4/2023 22:48 | Company has indemnity, compensation will be paid for by the UK government/tax payer. | angus mcoatup | |
13/4/2023 22:46 | No one wants to talk about the ongoing law suits against AZN? | angus mcoatup | |
13/4/2023 15:27 | All Time High! | gateside | |
12/4/2023 14:46 | Switched to GNC | blackhorse23 | |
12/4/2023 10:34 | Wonder if AZN have ever considered a share split?Though with it being the largest company in the FTSE100 a share price of 11800p does not really affect liquidity. | gateside | |
09/4/2023 20:16 | Header updated with dates for 2023 | gateside | |
07/4/2023 23:08 | Your hindsight is a wonderful thing not mine, speak for yourself. | angus mcoatup | |
30/3/2023 13:51 | Thanks 1knocker, interesting. My reference to 'buying mode' was for this stock only, not for stocks generally. Good luck. | mayers | |
30/3/2023 13:09 | mayers, I was very lucky and my 118.5 limit order to sell did trigger. You may recall that there was quite a lot of euphoria about at that time as to AZN's prospects of going well into the 120s. It is not so much that I am now in buying mode. I have a stack of 'out of the money' limit orders to buy and to sell in across my portfolio all the time. Most don't trigger, but in a volatile market, the odd one will. The winning on AZN were exceptional, but shows that it can happen. I had two round trips on FRES in quick succession, and another two on Shell as well. In a market like this we need to make the most of volatility. | 1knocker | |
30/3/2023 11:03 | Some lawyer bloke on bbc saying there is a time limit of one year for vaccine injured to file cases against AZN. | angus mcoatup | |
27/3/2023 15:57 | Nice dividend paid into my ii account this morning. | philanderer | |
15/3/2023 15:39 | Berenberg cuts AstraZeneca price target to 12,400 (12,600) pence - 'buy' | philanderer | |
06/3/2023 07:58 | AstraZeneca noted positive high-level results from an analysis of the ongoing Destiny-PanTumor02 phase II trial for Enhertu. Enhertu, or trastuzumab deruxtecan, met the target for objective response rate and showed a durable response across multiple HER2-expressive advanced solid tumours in heavily pretreated patients. Enhertu is being jointly commercialised by Astra and Daiichi Sankyo. | sarkasm |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions